-
Tytuł:
-
Comparison of Intra-Socket Bupivacaine Administration Versus Oral Mefenamic Acid Capsule for Postoperative Pain Management Following Removal of Impacted Mandibular Third Molars.
-
Autorzy:
-
Talimkhani I; Chief Resident of Oral and Maxillofacial Surgery, Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Hamadan University of Medical Sciences, Hamadan, Iran.
Jamalpour MR; Associate Professor, Department of Oral and Maxillofacial Surgery, Dental Implants Research Center, Faculty of Dentistry, Hamadan University of Medical Sciences, Hamadan, Iran. Electronic address: .
Babaei H; Oral and Maxillofacial Surgeon, Dental Implants Research Center, Faculty of Dentistry, Hamadan University of Medical Sciences, Hamadan, Iran.
Faradmal J; Associate Professor, Modeling of Noncommunicable Diseases Research Center and Department of Biostatistics and Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran.
-
Źródło:
-
Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons [J Oral Maxillofac Surg] 2019 Jul; Vol. 77 (7), pp. 1365-1370. Date of Electronic Publication: 2019 Jan 26.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: [Philadelphia, PA : W.B. Saunders Co., c1982-
-
MeSH Terms:
-
Anti-Inflammatory Agents, Non-Steroidal*/administration & dosage
Bupivacaine*/administration & dosage
Mefenamic Acid*/administration & dosage
Pain Management*
Tooth Extraction*
Tooth, Impacted*
Capsules ; Double-Blind Method ; Female ; Humans ; Male ; Mandible ; Molar, Third ; Pain, Postoperative
-
Substance Nomenclature:
-
0 (Anti-Inflammatory Agents, Non-Steroidal)
0 (Capsules)
367589PJ2C (Mefenamic Acid)
Y8335394RO (Bupivacaine)
-
Entry Date(s):
-
Date Created: 20190222 Date Completed: 20200807 Latest Revision: 20200807
-
Update Code:
-
20240104
-
DOI:
-
10.1016/j.joms.2019.01.021
-
PMID:
-
30790529
-
Purpose: Surgical removal of impacted third molar teeth is one of the most common surgical procedures performed in oral and maxillofacial surgery. Postoperative pain is a common and predictable occurrence after maxillofacial surgery.
Materials and Methods: This randomized double-blind clinical trial was conducted with a crossover design in which each patient served as his or her own control. Forty-six patients with similar bilateral impacted lower third molars were selected. In each patient, the intervention and control sides of the mandible were randomly determined at the end of surgery. If the removed tooth was in the intervention side, then the patient would receive bupivacaine and a placebo of mefenamic acid. If the impacted tooth was in the control side, then the patient would receive a mefenamic acid capsule and a placebo of bupivacaine. Pain severity was assessed using a visual analog scale. Data were analyzed using paired-sample t test and a P value less than .05 was considered statistically significant.
Results: Of 46 participants originally recruited, 43 were included in the present study. The mean postoperative pain score in patients who received bupivacaine was increased to a maximum 4 hours, with marked improvements after this time. The mean intensity of pain after administration of bupivacaine was lower than that of mefenamic acid capsules at different time points. Statistical analysis showed a relevant difference in pain intensity between the 2 study groups.
Conclusion: The results of the present study showed that local administration of bupivacaine relieves postoperative pain after surgical removal of impacted third molar teeth.
(Copyright © 2019 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.)
